Tyra Biosciences, Inc. Common Stock (TYRA)
PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 87
- Market Cap
- $2.0B
About Tyra Biosciences, Inc. Common Stock
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
SentiSense also tracks daily options readings for Tyra Biosciences, Inc. Common Stock: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Tyra Biosciences, Inc. Common Stock stock analysis, sentiment tracking, and market intelligence on SentiSense.